Literature DB >> 20696867

The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.

Hsun-Cheng Su1, Kevin Ramkissoon, Janet Doolittle, Martha Clark, Jainab Khatun, Ashley Secrest, Matthew C Wolfgang, Morgan C Giddings.   

Abstract

Microbes have developed resistance to nearly every antibiotic, yet the steps leading to drug resistance remain unclear. Here we report a multistage process by which Pseudomonas aeruginosa acquires drug resistance following exposure to ciprofloxacin at levels ranging from 0.5× to 8× the initial MIC. In stage I, susceptible cells are killed en masse by the exposure. In stage II, a small, slow to nongrowing population survives antibiotic exposure that does not exhibit significantly increased resistance according to the MIC measure. In stage III, exhibited at 0.5× to 4× the MIC, a growing population emerges to reconstitute the population, and these cells display heritable increases in drug resistance of up to 50 times the original level. We studied the stage III cells by proteomic methods to uncover differences in the regulatory pathways that are involved in this phenotype, revealing upregulation of phosphorylation on two proteins, succinate-semialdehyde dehydrogenase (SSADH) and methylmalonate-semialdehyde dehydrogenase (MMSADH), and also revealing upregulation of a highly conserved protein of unknown function. Transposon disruption in the encoding genes for each of these targets substantially dampened the ability of cells to develop the stage III phenotype. Considering these results in combination with computational models of resistance and genomic sequencing results, we postulate that stage III heritable resistance develops from a combination of both genomic mutations and modulation of one or more preexisting cellular pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696867      PMCID: PMC2976116          DOI: 10.1128/AAC.00762-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  Comparative killing rates of fluoroquinolones and cell wall-active agents.

Authors:  J C Fung-Tomc; E Gradelski; L Valera; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Proteomic approach to understanding antibiotic action.

Authors:  Julia Elisabeth Bandow; Heike Brötz; Lars Ingo Ole Leichert; Harald Labischinski; Michael Hecker
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

3.  Bacterial persistence as a phenotypic switch.

Authors:  Nathalie Q Balaban; Jack Merrin; Remy Chait; Lukasz Kowalik; Stanislas Leibler
Journal:  Science       Date:  2004-08-12       Impact factor: 47.728

4.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.

Authors:  H Mouneimné; J Robert; V Jarlier; E Cambau
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Bacterial persistence: a model of survival in changing environments.

Authors:  Edo Kussell; Roy Kishony; Nathalie Q Balaban; Stanislas Leibler
Journal:  Genetics       Date:  2005-01-31       Impact factor: 4.562

Review 7.  Mechanisms of action and resistance of older and newer fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

Review 8.  Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions.

Authors:  Herbert P Schweizer
Journal:  Genet Mol Res       Date:  2003-03-31

9.  DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa.

Authors:  M Yonezawa; M Takahata; N Matsubara; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 10.  Pseudomonal infections in patients with COPD: epidemiology and management.

Authors:  David Lieberman; Devora Lieberman
Journal:  Am J Respir Med       Date:  2003
View more
  11 in total

1.  Comparative genome analysis of ciprofloxacin-resistant Pseudomonas aeruginosa reveals genes within newly identified high variability regions associated with drug resistance development.

Authors:  Hsun-Cheng Su; Jainab Khatun; Dona M Kanavy; Morgan C Giddings
Journal:  Microb Drug Resist       Date:  2013-06-29       Impact factor: 3.431

Review 2.  Siderophores in Iron Metabolism: From Mechanism to Therapy Potential.

Authors:  Briana R Wilson; Alexander R Bogdan; Masaki Miyazawa; Kazunori Hashimoto; Yoshiaki Tsuji
Journal:  Trends Mol Med       Date:  2016-11-04       Impact factor: 11.951

3.  Enzymatic quorum quenching increases antibiotic susceptibility of multidrug resistant Pseudomonas aeruginosa.

Authors:  S Kiran; P Sharma; K Harjai; N Capalash
Journal:  Iran J Microbiol       Date:  2011-03

4.  Lactonase-expressing Lactobacillus plantarum NC8 attenuates the virulence factors of multiple drug resistant Pseudomonas aeruginosa in co-culturing environment.

Authors:  Sudha Joshi; Amanjot Kaur; Prince Sharma; Kusum Harjai; Neena Capalash
Journal:  World J Microbiol Biotechnol       Date:  2014-03-27       Impact factor: 3.312

5.  Antiquorum sensing activity of silver nanoparticles in P. aeruginosa: an in silico study.

Authors:  Syed Ghazanfar Ali; Mohammad Azam Ansari; Qazi Mohd Sajid Jamal; Haris M Khan; Mohammad Jalal; Hilal Ahmad; Abbas Ali Mahdi
Journal:  In Silico Pharmacol       Date:  2017-10-20

6.  Effect of Biosynthesized ZnO Nanoparticles on Multi-Drug Resistant Pseudomonas Aeruginosa.

Authors:  Syed Ghazanfar Ali; Mohammad Azam Ansari; Mohammad A Alzohairy; Mohammad N Alomary; Mohammad Jalal; Sami AlYahya; Sarah Mousa Maadi Asiri; Haris M Khan
Journal:  Antibiotics (Basel)       Date:  2020-05-17

7.  A Pilot Study of the Synergy between Two Antimicrobial Peptides and Two Common Antibiotics.

Authors:  Franziska Kampshoff; Mark D P Willcox; Debarun Dutta
Journal:  Antibiotics (Basel)       Date:  2019-05-09

8.  Ciprofloxacin-Modified Degradable Hybrid Polyurethane-Polylactide Porous Scaffolds Developed for Potential Use as an Antibacterial Scaffold for Regeneration of Skin.

Authors:  Carayon Iga; Terebieniec Agata; Łapiński Marcin; Filipowicz Natalia; Kucińska-Lipka Justyna
Journal:  Polymers (Basel)       Date:  2020-01-09       Impact factor: 4.329

9.  Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment.

Authors:  Jennifer A Bartell; David R Cameron; Biljana Mojsoska; Janus Anders Juul Haagensen; Tacjana Pressler; Lea M Sommer; Kim Lewis; Søren Molin; Helle Krogh Johansen
Journal:  PLoS Pathog       Date:  2020-12-14       Impact factor: 6.823

10.  RNASeq Based Transcriptional Profiling of Pseudomonas aeruginosa PA14 after Short- and Long-Term Anoxic Cultivation in Synthetic Cystic Fibrosis Sputum Medium.

Authors:  Muralidhar Tata; Michael T Wolfinger; Fabian Amman; Nicole Roschanski; Andreas Dötsch; Elisabeth Sonnleitner; Susanne Häussler; Udo Bläsi
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.